AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06450899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo arm individuals will receive a non-identical inert generic placebo tablet containing microcrystalline cellulose provided by Belmar Pharma Solutions. Placebo tablets will be taken at the same time and frequency as the study intervention drug.
Study NCT05003505 — intervention group
Intervention type: OTHER
Intervention: Follow up
Description: Participants will be followed up at 6, 12 and 24 months with the test of enous blood, vaginal secretions, faeces, and cervical exfoliated cells.
Study NCT06394050 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: there is no intervention
Study NCT05204719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic Delivery Room Continuous Positive Airway Pressure
Description: Prophylactic Delivery Room Continuous Positive Airway Pressure (DR-CPAP) of 5-6 cm H20 will be provided for 20 minutes through the face mask or the appropriate size of nasal prong after the initial steps as per the participating institution's neonatal resuscitation protocol.
Study NCT05659953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMT503
Description: Subjects will receive one of several different oral doses of LMT503 once daily
Study NCT05659953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive one of several different oral doses of Placebo once daily
Study NCT05839964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CBN and CBD
Description: CBN and CBD in Gummy Format
Study NCT05839964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CBN and CBD
Description: CBN and CBD in Gummy Format
Study NCT05387200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masibone S
Description: The investigators will evaluate the change of bone mineral density at lumbar spine measured by DEXA after 48 weeks of alendronate sodium trihydrate 70mg (oral solution) 1 bottle weekly and cholecalciferol 1000U/calcium 100mg 1T daily use.
Study NCT05387200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamax
Description: The investigators will evaluate the change of bone mineral density at lumbar spine measured by DEXA after 48 weeks of alendronate sodium 70mg (oral tablet) 1T weekly and cholecalciferol 1000U/calcium 100mg 1T daily use.
Study NCT06036225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Remote prehabilitation multi-component.
Study NCT05944302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR group
Description: Eye Movement Desensitization and Reprocessing
Study NCT05122338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Before the induction of anesthesia, normal saline is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Study NCT05122338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Before the induction of anesthesia, 0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Study NCT05122338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound lidocaine
Description: Before the induction of anesthesia, 0.4% compound lidocaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Study NCT05122338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: Before the induction of anesthesia, 0.4mg/kg esketamine is used for bilateral transversus abdominis plane block
Study NCT05074992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Study NCT05778604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physio-feedback
Description: The researcher presents the BTrackS software to display the participant's BBS score (s) with interpretations including: (1) baseline, post-baseline, percent of changes; (2) comparison to sex and age group; and (3) levels of fall risk. The researcher will categorize participants into four groups (irrational \| incongruent \| congruent \| rational) based on the fall risk appraisal (FRA) matrix and plots the position on one of the four quadrants in the FRA matrix chart. The researcher will provide physio-feedback to participants at baseline and week 9.
Study NCT05778604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive reframing
Description: Cognitive reframing will be based on the fall risk appraisal (FRA) matrix. We will present the FRA matrix and activities will be tailored based on the quadrant that participant fits. Quadrant 1 (Irrational) focus on increasing balance confidence and maintaining exercise. Quadrant 2 (Incongruent) focus on individual fall risk factors from the CDC fall risk checklist, enhance fall risk awareness, and participate in the exercise. Quadrant 3 (Congruent) focus on individual fall risk factors from the CDC fall checklist and participate in the exercise. Quadrant 4 (Rational) encourage to maintain exercise.
Study NCT05778604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led exercises
Description: The peer-led exercise is focused on balance, strength training, and incorporating exercises into daily activities. A trained peer coach (PC) will lead the group-based exercises for 60 mins (8-10/group). Exercise training consists of four sets: a) warm-up (seated), b) strength for upper and lower body (seated and standing), c) balance (standing and moving), and d) stretching of the lower and upper body. We will provide an exercise booklet (English/Spanish version) with illustrations that highlight steps for each set of exercises and a wide variety of exercises to integrate into daily activities (e.g., cooking). Participants will be instructed to complete a weekly exercise log to record types and duration of activity performed at home.
Study NCT05778604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDC older adults fall prevention
Description: Participants will receive an information pamphlet about falls (English or Spanish version) developed by the CDC (Stopping Elderly Accidents, Deaths, and Injuries (STEADI)-Older Adult Fall Prevention). The pamphlet contains information on fall risk, how to prevent falls, check for safety, postural hypotension and chair rise exercise including what you can do to prevent falls. The participants will be encouraged to discuss fall prevention with a primary care provider and continue normal activities (treatment-as-usual) for 6 months. Participants will receive monthly follow-up phone calls from the study team to record a monthly fall incidence log.
Study NCT06322186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready-Heat Chemical Heating Blankets
Description: Ready-Heat blankets are 4-panel half blankets that generate an oxygen-activated exothermic effect in 8-15 minutes (i.e., no electricity required), providing warmth over 8 hours at up to 40 degrees Celsius.
Study NCT06322186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warmed blankets or FAWB
Description: The current standard of care for hypothermic patients is applying two warmed blankets or forced air warming blankets (FAWB).
Study NCT05266989 — intervention group
Intervention type: OTHER
Intervention: Transcranial Direct Current Stimulation
Description: Non-invasive technique that modulates the excitability of the cortex by applying low-intensity current
Study NCT06430970 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: endoscopy
Description: upper and lower endoscopy
Study NCT05826743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COLO BT™
Description: A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma after surgery for only patients who need it (do not have a healed anastomosis)
Study NCT05826743 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stoma Creation
Description: Protective ileostomy
Study NCT06242132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel tablet
Description: Efficacy and safety of a 300mg loading dose of clopidogrel administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study NCT06242132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 MG
Description: Efficacy and safety of 200 mg cilostazole followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study NCT06413992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: During the maintenance phase of treatment. Oral administration of Fluzoparib capsules at a dose of 150mg（N=78 participants）, once in the morning and once in the evening until disease progression, intolerable toxicity, death, or up to a maximum of 2 years.
Study NCT06413992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: During the maintenance phase of treatment. Camrelizumab, 200 mg administered intravenously every 3 weeks until disease progression, intolerable toxicity, death, or up to 2 years.
Study NCT06413992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: During the maintenance phase of treatment. Camrelizumab, 200 mg administered intravenously every 3 weeks until disease progression, intolerable toxicity, death, or up to 2 years.
Study NCT06413992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel (albumin bound)
Description: Paclitaxel (albumin-bound) for injection, 260 mg/m\^2 administered intravenously in 3-week cycles for 6 cycles.
Study NCT06413992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel (albumin bound)
Description: Paclitaxel (albumin-bound) for injection, 260 mg/m\^2 administered intravenously in 3-week cycles for 6 cycles.
Study NCT06413992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin injection
Description: AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator
Study NCT06413992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin injection
Description: AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator
Study NCT06413992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator
Study NCT06413992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC=5 Intravenous dosing is administered every 3 weeks for a total of 6 treatment cycles. Specific dosing cycles may be determined by the investigator
Study NCT06413992 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External irradiation
Description: Non-essential, decision to combine is made by the principal investigator based on the patient's condition.
Study NCT06413992 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External irradiation
Description: Non-essential, decision to combine is made by the principal investigator based on the patient's condition.
Study NCT06262321 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Palliative Radiotherapy
Description: Prophylactic Palliative Radiotherapy
Study NCT04262388 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
Study NCT04262388 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab is a human immunoglobulin G1 lambda monoclonal antibody (mAb) with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab selectively binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. This, in turn, leads to increased antitumor immunity.
Study NCT06324162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bracket removal pliers, LODI
Description: Brackets on the right side of both dental arches were debonded using the lift-off debonding instrument (LODI), while on the left side, the bracket removal pliers (BRP). The residual adhesive was removed through two methods (manual in the upper arch and rotary in the lower). The same scale was employed to assess pain levels during brackets and adhesive removal.
Study NCT06161246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Beauty Bar
Description: A vibrating beauty bar will be used at the injection site for patient comfort.
Study NCT05903898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI software StrokeSens (Circle NVI)
Description: Computed tomography (CT) and computed tomography angiography (CTA) imaging studies acquired upon admission will be assessed by the AI software StrokeSENS (Circle NVI). StrokeSENS is CE marked and available for clinical diagnostic purposes in the EU and UK.The software will be a decision support tool in addition to standard radiological services available in all primary stroke centers in Northern Norway where image interpretation is done by a radiologist or resident in radiology. The software can automatically evaluate the presence of ischemic changes in the vascular territory of the middle cerebral artery according to the Alberta Stroke Program Early CT Score (ASPECTS) and occlusions in the intracranial segment of the internal carotid artery and the proximal segments of the middle cerebral artery (MCA). Output to radiologists will be automated ASPECT scoring, automated search for LVO or MeVO.
Study NCT05781906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523
Description: D1-D7: HMPL-523 Tablet 300 mg QD
Study NCT05781906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 µCi [14C]HMPL-523
Description: D8: \[14C\] HMPL-523 Suspension 300 mg/150 μCi Single dose
Study NCT06554795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1419
Description: Administered Injection of Vein (I.V.)
Study NCT05098834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENLIGHT 2100 ventilatory electrical impedance tomograph
Description: The ENLIGHT 2100 system will remain connected to the patient for data acquisition from immediately prior to initiation of the ERT until up to 24 hours following extubation.
Study NCT05179928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block (ESPB)
Description: Postoperative Bilateral Ultrasound-guided ESPB
Study NCT05179928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus Sheath Block (RSB)
Description: Postoperative Bilateral Ultrasound-guided RSB
Study NCT05199337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-d5
Description: ZN-d5 will be administered orally
Study NCT05820932 — intervention group
Intervention type: GENETIC
Intervention: Blood-based assay
Description: Blood samples will be collected
Study NCT05820932 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive assessments
Description: Cognitive assessments will be both participant- and partner-reported
Study NCT05820932 — intervention group
Intervention type: OTHER
Intervention: Quality of Life Surveys
Description: Participant-reported Quality of Life Surveys
Study NCT05766800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serplulimab
Description: Specified dose on specified days
Study NCT05766800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Specified dose on specified days
Study NCT05766800 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Serplulimab
Description: Specified dose on specified days
Study NCT05766800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT05766800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT05766800 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Specified dose on specified days
Study NCT05766800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Specified dose on specified days
Study NCT05766800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days
Study NCT05766800 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pemetrexed
Description: Specified dose on specified days
Study NCT05766800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Specified dose on specified days
Study NCT05766800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Specified dose on specified days
Study NCT05766800 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nab-paclitaxel
Description: Specified dose on specified days
Study NCT05766800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal paclitaxel
Description: Specified dose on specified days
Study NCT05766800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal paclitaxel
Description: Specified dose on specified days
Study NCT05766800 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal paclitaxel
Description: Specified dose on specified days
Study NCT05766800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients with stage IIIB-IIIC non-small cell lung cancer are treated with nab-paclitaxel/pemetrexed plus carboplatin and serplulimab for 4 cycles. Those with downstaged and resectable tumors after chemoimmunotherapy are randomised into surgical treatment arm and radiotherapy arm, and those with tumors still unresectable after chemoimmunotherapy will receive non-surgical treatment in department of medical oncology in the third arm.
Study NCT05766800 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Patients with stage IIIB-IIIC non-small cell lung cancer are treated with nab-paclitaxel/pemetrexed plus carboplatin and serplulimab for 4 cycles. Those with downstaged and resectable tumors after chemoimmunotherapy are randomised into surgical treatment arm and radiotherapy arm, and those with tumors still unresectable after chemoimmunotherapy will receive non-surgical treatment in department of medical oncology in the third arm.
Study NCT05766800 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: Patients with stage IIIB-IIIC non-small cell lung cancer are treated with nab-paclitaxel/pemetrexed plus carboplatin and serplulimab for 4 cycles. Those with downstaged and resectable tumors after chemoimmunotherapy are randomised into surgical treatment arm and radiotherapy arm, and those with tumors still unresectable after chemoimmunotherapy will receive non-surgical treatment in department of medical oncology in the third arm.
Study NCT06388512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prototype prone positioning device
Description: The prototype prone positioning device will be used during neurosurgical procedures utilizing intraoperative MRI.
Study NCT04733521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-43
Description: SC-43 oral, every day of 21-day cycle
Study NCT04733521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 75mg/m2 on day 1 of 21-day cycle
Study NCT04282161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axys EX device
Description: Rotational atherectomy system for endovascular treatment of peripheral arterial disease prior to adjunctive therapy, if needed
Study NCT05516381 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optetrak Logic CR Knee System
Description: The OPTETRAK® Comprehensive Knee System consists of the OPTETRAK® Total Knee System and the OPTETRAK Logic® Total Knee System. The OPTETRAK Comprehensive Knee System comprises both non-porous and porous knee prostheses for use in total-knee joint replacement procedures. (In the USA, the OPTETRAK Comprehensive Knee System is indicated for cemented use only, except for the OPTETRAK Logic PS and CR Porous Femoral Components, which are indicated for cemented or cementless use.) The system includes various sizes and types of modular femoral components, tibial components, patellar components, and accessories for use in primary and revision applications.
Study NCT05707728 — intervention group
Intervention type: DEVICE
Intervention: intraoperative ultrasound
Description: intraoperative cranial ultrasound
Study NCT05736380 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebellar rTMS
Description: 250 pulses at 10 Hertz over the cerebellum